Financial Ratios NFL Biosciences

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Real-time Euronext Paris 03:56:44 2026-08-26 EDT			5-day change	1st Jan Change
0.8900 ^EUR	-0.56%		+2.53%	-24.45%

07-28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
07-07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI

b1002f8dd37ffeb7bb68a9361f63d75._qUj2bQXDXIX9i2V5FA4Xg6fqvgKozSpTWCd71JAnuI.ssh2g9V_Qkp5vh74qAVsNkv338FewlX-Gi32vTx5qobM9Hu_xFVVNnCRTg

Published financial data: NFL BIOSCIENCES

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Other Revenues, Total	39	22	200K	46	188
Total Revenues	39	22	200K	46	188
Cost of Goods Sold, Total	531K	2.24M	3.48M	1.55M	2.52M
Gross Profit	-531K	-2.24M	-3.28M	-1.55M	-2.52M
Selling General & Admin Expenses, Total	278K	722K	775K	1.07M	1.18M
Depreciation & Amortization - (IS)	43.5K	52.44K	56.06K	67.14K	86.4K
Other Operating Expenses	49.79K	73.15K	122K	105K	82.55K
Other Operating Expenses, Total	371K	847K	953K	1.24M	1.35M
Operating Income	-902K	-3.08M	-4.23M	-2.79M	-3.87M
Interest Expense, Total	-538	-493	-6.51K	-304	-14.19K
Interest And Investment Income	527	-	94.86K	67.29K	31.18K
Net Interest Expenses	-11	-493	88.36K	66.99K	16.99K
Currency Exchange Gains (Loss)	-	4.84K	-395	-1.7K	-2.11K
Other Non Operating Income (Expenses)	-218K	178K	30.59K	8.56K	-
EBT, Excl. Unusual Items	-1.12M	-2.9M	-4.11M	-2.72M	-3.86M
Other Unusual Items	-	39.02K	-	-	-
EBT, Incl. Unusual Items	-1.12M	-2.86M	-4.11M	-2.72M	-3.86M
Income Tax Expense	-141K	-418K	-366K	-635K	-540K
Earnings From Continuing Operations	-978K	-2.44M	-3.75M	-2.08M	-3.32M
Net Income to Company	-978K	-2.44M	-3.75M	-2.08M	-3.32M
Net Income - (IS)	-978K	-2.44M	-3.75M	-2.08M	-3.32M
Net Income to Common Incl Extra Items	-978K	-2.44M	-3.75M	-2.08M	-3.32M
Net Income to Common Excl. Extra Items	-978K	-2.44M	-3.75M	-2.08M	-3.32M
Per Share Items
Net EPS - Basic	-0.19	-0.47	-0.46	-0.21	-0.26
Basic EPS - Continuing Operations	-0.19	-0.47	-0.46	-0.21	-0.26
Basic Weighted Average Shares Outstanding	5.23M	5.23M	8.16M	10.1M	13.01M
Net EPS - Diluted	-0.19	-0.47	-0.46	-0.21	-0.26
Diluted EPS - Continuing Operations	-0.19	-0.47	-0.46	-0.21	-0.26
Diluted Weighted Average Shares Outstanding	5.23M	5.23M	8.16M	10.1M	13.01M
Normalized Basic EPS	-0.13	-0.35	-0.31	-0.17	-0.19
Normalized Diluted EPS	-0.13	-0.35	-0.31	-0.17	-0.19
Supplemental Items
EBITDA	-858K	-3.03M	-4.17M	-2.72M	-3.79M
EBITA	-902K	-3.08M	-4.23M	-2.79M	-3.87M
EBIT	-902K	-3.08M	-4.23M	-2.79M	-3.87M
Total Revenues (As Reported)	39	22	200K	46	188
Effective Tax Rate - (Ratio)	12.62	14.6	8.91	23.39	13.99
Normalized Net Income	-700K	-1.81M	-2.57M	-1.7M	-2.41M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	3.04M	1.05M	2.34M	1.91M	2M
Short Term Investments	165K	161K	191K	200K	200K
Total Cash And Short Term Investments	3.2M	1.21M	2.53M	2.11M	2.2M
Other Receivables	220K	742K	1.11M	1.06M	966K
Total Receivables	220K	742K	1.11M	1.06M	966K
Prepaid Expenses	134K	301K	182K	168K	238K
Total Current Assets	3.56M	2.26M	3.82M	3.34M	3.41M
Gross Property Plant And Equipment	39.38K	4.73K	48.56K	180K	185K
Accumulated Depreciation	-37.39K	-2.64K	-39.5K	-55.02K	-83.83K
Net Property Plant And Equipment	1.99K	2.09K	9.06K	125K	101K
Long-term Investments	7	-	-	-	-
Other Intangibles, Total	124K	136K	141K	145K	157K
Other Long-Term Assets, Total	-	-	1	-1	-
Total Assets	3.69M	2.4M	3.97M	3.61M	3.66M
Liabilities
Accounts Payable, Total	120K	1.19M	2.16M	1.15M	510K
Accrued Expenses, Total	65.58K	208K	-	255K	245K
Short-term Borrowings	7	7	-	-	-
Current Portion of Long-Term Debt	-	-	-	21.32K	-
Current Income Taxes Payable	-	-	204K	-	-
Other Current Liabilities	-	-	-	-	-
Total Current Liabilities	186K	1.4M	2.37M	1.42M	755K
Long-Term Debt	85K	83.25K	62.17K	19.65K	435K
Long-Term Leases	-	-	-	-	148K
Other Non Current Liabilities	127K	72.98K	1.19M	1.19M	2.02M
Total Liabilities	398K	1.55M	3.62M	2.63M	3.36M
Common Stock, Total	157K	157K	243K	295K	380K
Additional Paid In Capital	4.11M	4.11M	7.27M	2.76M	3.24M
Retained Earnings	-978K	-3.42M	-7.17M	-2.08M	-3.32M
Comprehensive Income and Other	-	-1	-	1	1
Total Common Equity	3.29M	844K	350K	976K	306K
Total Equity	3.29M	844K	350K	976K	306K
Total Liabilities And Equity	3.69M	2.4M	3.97M	3.61M	3.66M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	5.23M	5.23M	8.16M	9.83M	12.67M
ECS Total Common Shares Outstanding	5.23M	5.23M	8.16M	9.83M	12.67M
Book Value / Share	0.63	0.16	0.04	0.1	0.02
Tangible Book Value	3.16M	708K	209K	831K	149K
Tangible Book Value Per Share	0.6	0.14	0.03	0.08	0.01
Total Debt	85.01K	83.26K	62.17K	40.98K	583K
Net Debt	-3.12M	-1.13M	-2.47M	-2.07M	-1.62M
Account Code - Inventory Valuation	3	3	-	3	3
Machinery, Total	35.76K	-	48.56K	180K	185K
Full Time Employees	4	4	-	4	4

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Supplemental Items
Change In Net Working Capital		101K	-521K	-724K	900K	625K

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-26.45	-63.38	-83.07	-46.01	-66.56
Return on Total Capital	-31.25	-89.63	-394.81	-243.97	-253.96
Return On Equity %	-56.92	-118.29	-627.41	-313.76	-517.39
Return on Common Equity	-56.92	-118.29	-627.41	-313.76	-517.39
Margin Analysis
Gross Profit Margin %	-1.36M	-10.16M	-1.64K	-3.36M	-1.34M
SG&A Margin	713K	3.28M	387.5	2.33M	630K
EBITDA Margin %	-2.2M	-13.78M	-2.09K	-5.92M	-2.01M
EBITA Margin %	-2.31M	-14.01M	-2.12K	-6.07M	-2.06M
EBIT Margin %	-2.31M	-14.01M	-2.12K	-6.07M	-2.06M
Income From Continuing Operations Margin %	-2.51M	-11.11M	-1.87K	-4.52M	-1.76M
Net Income Margin %	-2.51M	-11.11M	-1.87K	-4.52M	-1.76M
Net Avail. For Common Margin %	-2.51M	-11.11M	-1.87K	-4.52M	-1.76M
Normalized Net Income Margin	-1.79M	-8.24M	-1.28K	-3.69M	-1.28M
Asset Turnover
Asset Turnover	0	0	0.06	0	0
Fixed Assets Turnover	0.04	0.01	35.88	0	0
Short Term Liquidity
Current Ratio	19.16	1.62	1.61	2.35	4.51
Quick Ratio	18.44	1.4	1.54	2.23	4.2
Average Days Payable Outstanding	56.97	106.71	175.84	391.9	120.1
Long Term Solvency
Total Debt/Equity	2.59	9.86	17.77	4.2	190.3
Total Debt / Total Capital	2.52	8.98	15.09	4.03	65.55
LT Debt/Equity	2.59	9.86	17.77	2.01	190.3
Long-Term Debt / Total Capital	2.52	8.98	15.09	1.93	65.55
Total Liabilities / Total Assets	10.79	64.77	91.19	72.95	91.64
EBIT / Interest Expense	-1.68K	-6.25K	-650.23	-9.18K	-272.89
EBITDA / Interest Expense	-1.6K	-6.15K	-641.62	-8.96K	-266.8
(EBITDA - Capex) / Interest Expense	-1.6K	-6.15K	-641.62	-8.96K	-266.8
Total Debt / EBITDA	-0.1	-0.03	-0.01	-0.02	-0.15
Net Debt / EBITDA	3.63	0.37	0.59	0.76	0.43
Total Debt / (EBITDA - Capex)	-0.1	-0.03	-0.01	-0.02	-0.15
Net Debt / (EBITDA - Capex)	3.63	0.37	0.59	0.76	0.43
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	1.2K	-43.59	909K	-99.98	308.7
Gross Profit, 1 Yr. Growth %	213.36	321.28	46.61	-52.83	62.89
EBITDA, 1 Yr. Growth %	210.92	253.08	37.73	-34.77	39.05
EBITA, 1 Yr. Growth %	183.58	241.87	37.21	-34.05	38.8
EBIT, 1 Yr. Growth %	183.58	241.87	37.21	-34.05	38.8
Earnings From Cont. Operations, 1 Yr. Growth %	274.09	149.78	53.28	-44.44	59.45
Net Income, 1 Yr. Growth %	274.09	149.78	53.28	-44.44	59.45
Normalized Net Income, 1 Yr. Growth %	252.01	159.07	41.77	-33.94	42.02
Diluted EPS Before Extra, 1 Yr. Growth %	-	149.78	-1.67	-55.12	23.79
Net Property, Plant and Equip., 1 Yr. Growth %	-	5.13	333.7	1.28K	-19.13
Total Assets, 1 Yr. Growth %	539.08	-35	65.75	-9.09	1.48
Tangible Book Value, 1 Yr. Growth %	7.6K	-77.61	-70.5	297.86	-82.05
Common Equity, 1 Yr. Growth %	2.09K	-74.33	-58.54	179.02	-68.65
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-	170.8	7.06K	44.6	-96.94
Gross Profit, 2 Yr. CAGR %	-	263.34	148.52	-16.84	-12.34
EBITDA, 2 Yr. CAGR %	-	231.33	120.53	-5.21	-4.76
EBITA, 2 Yr. CAGR %	-	211.36	116.58	-4.87	-4.32
EBIT, 2 Yr. CAGR %	-	211.36	116.58	-4.87	-4.32
Earnings From Cont. Operations, 2 Yr. CAGR %	-	205.68	95.67	-7.72	-5.88
Net Income, 2 Yr. CAGR %	-	205.68	95.67	-7.72	-5.88
Normalized Net Income, 2 Yr. CAGR %	-	201.99	91.65	-3.23	-3.14
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	56.72	-33.57	-25.46
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-	113.53	673.24	233.89
Total Assets, 2 Yr. CAGR %	-	103.82	3.8	22.76	-3.95
Tangible Book Value, 2 Yr. CAGR %	-	315.21	-74.3	8.33	-15.5
Common Equity, 2 Yr. CAGR %	-	137.19	-67.37	7.56	-6.47
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	-	3.95K	5.66	104.45
Gross Profit, 3 Yr. CAGR %	-	-	168.49	42.83	4.05
EBITDA, 3 Yr. CAGR %	-	-	147.28	46.93	7.7
EBITA, 3 Yr. CAGR %	-	-	136.94	45.71	7.9
EBIT, 3 Yr. CAGR %	-	-	136.94	45.71	7.9
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	142.85	28.61	10.74
Net Income, 3 Yr. CAGR %	-	-	142.85	28.61	10.74
Normalized Net Income, 3 Yr. CAGR %	-	-	134.71	34.37	9.98
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	-	3.3	-18.25
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	-	297.61	264.31
Total Assets, 3 Yr. CAGR %	-	-	90.25	-0.69	15.21
Tangible Book Value, 3 Yr. CAGR %	-	-	71.97	-35.95	-40.5
Common Equity, 3 Yr. CAGR %	-	-	32.62	-33.28	-28.68
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	-	-	-	128.77
Gross Profit, 5 Yr. CAGR %	-	-	-	-	71.58
EBITDA, 5 Yr. CAGR %	-	-	-	-	68.83
EBITA, 5 Yr. CAGR %	-	-	-	-	64.86
EBIT, 5 Yr. CAGR %	-	-	-	-	64.86
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	-	66.22
Net Income, 5 Yr. CAGR %	-	-	-	-	66.22
Normalized Net Income, 5 Yr. CAGR %	-	-	-	-	64.73
Total Assets, 5 Yr. CAGR %	-	-	-	-	44.74
Tangible Book Value, 5 Yr. CAGR %	-	-	-	-	29.42
Common Equity, 5 Yr. CAGR %	-	-	-	-	15.33